Business Wire

AI EdgeLabs Adds Advanced Risk and Compliance Center with Linux Audit Capabilities to Its AI Runtime Platform

13.1.2026 11:00:00 EET | Business Wire | Press release

Share

AI EdgeLabs, the pioneer in autonomous AI runtime platform, today announced the launch of Compliance Center and Linux Audit. Purpose-built for organizations facing NIS2, CRA, and global critical-infrastructure mandates, the new capabilities replace manual reporting and scan-based compliance with continuous visibility, automated control coverage, and real-time posture insights.

Key capabilities include:

  • A single Risk Score representing their current posture
  • Real-time compliance visibility for CRA and NIS2
  • Prioritized assets based on impact and criticality
  • Extended support for firmware, custom OS, and RTOS
  • Linux audit and configuration hardening insights
  • Automated, framework-specific checklists
  • Incident Reporting and Automated Response

“As NIS2 and the Cyber Resilience Act come into force, companies need continuous proof of compliance, not manual mapping or siloed visibility,” said Inna Ushakova, CEO of AI EdgeLabs. “This release provides real-time compliance posture, instant detection of vulnerabilities and misconfigurations and maps those to the incidents, and automated incident coverage. It finally gives teams the operational evidence regulators require and the autonomy distributed AI environments demand.”

For organizations navigating a complex regulatory landscape, the new Automated Compliance Center provides the essential visibility and evidence required for NIS2 and CRA readiness. It delivers real-time mapping, compliance proof, and automated reporting aligned with both frameworks.

“We built this architecture to cut through the noise of traditional security reporting,” said Oleg Mygryn, CTO of AI EdgeLabs. “By integrating custom OS verification with SBOM-based vulnerability detection, we give security teams a granular, prioritized view of their risk. Whether it’s a Linux misconfiguration or a firmware issue on a critical GPU node, our AI engine identifies the context and criticality, allowing teams to address the assets that matter most before they can be exploited.”

With Linux Audit and Compliance Center, AI EdgeLabs is extending its AI-native protection deeper into the runtime layer, giving organizations the continuous compliance visibility required by emerging regulations.

About AI EdgeLabs

AI EdgeLabs is an AI-native, autonomous runtime protection platform for regulated AI workloads, GPU clusters, edge, hybrid cloud, and sovereign environments. Built to secure regulated AI workloads and infrastructure in real-time, AI EdgeLabs delivers threat detection and response capabilities where CNAPPs can’t reach, ensuring the integrity of distributed infrastructure across the globe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113487666/en/

Contacts

Inna Ushakova, CEO
+19733235639
iu@edgelabs.ai
https://edgelabs.ai -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fedgelabs.ai&es
heet=54386807&newsitemid=20260113487666&lan=en-US&anchor=https%3A%2F%2Fedgelabs.
ai&index=4&md5=aee6c107d1ffc581bf549cabc940dddf
https://www.linkedin.com/company/ai-edgelabs/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fcompany%2Fai-edgelabs%2F&esheet=54386807&newsitemid=20260113487666&lan=en-U
S&anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fai-edgelabs%2F&index=5&md5=8
0ef1eb0fa50cdc98185ae72fed45f23

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye